This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

FDA Clears Enhanced Features On Fresenius Medical Care’s 2008T, The Most Technically Integrated Hemodialysis Delivery System

At the American Society of Nephrology’s Kidney Week 2011, Fresenius Medical Care (NYSE: FMS), the world’s largest provider of dialysis products and services, announced that it received U.S. Food and Drug Administration 510 (K) clearance to extend improved touch screen navigation on its most advanced hemodialysis delivery system, the 2008T. Effective immediately, all newly produced 2008T machines with Fresenius Clinical Data Exchange (CDX) will come with this enhancement.

Introduced a year ago at Kidney Week 2010, the 2008T is the first fully integrated therapy and management information system on the market. The 2008T combines Fresenius Medical Care’s most advanced hemodialysis delivery system with CDX providing caregivers, for the first time, chair-side access to the facility’s medical information system and dialysis treatment data.

“With all the key information a medical professional needs, immediately at hand, they can focus on patient care. The human factors engineering is an appreciation of how medical professionals actually work in the clinical setting. The 2008T puts key patient and treatment information more quickly at the clinicians’ fingertips,” said Jose A. Diaz-Buxo, MD, FACP, Chief Medical & Regulatory Affairs Officer, Fresenius Medical Care. “Simplicity, ease of use and readily available information allows care-givers more time to focus on the patient.”

About Fresenius Medical Care

Fresenius Medical Care (NYSE: FMS) is the world’s leading company devoted to patient-oriented renal therapy. Through more than 2,900 clinics in North America, Europe, Latin America, Asia-Pacific and Africa, we provide kidney dialysis treatments to approximately 228,000 patients worldwide. We are also the world's leading maker of dialysis products such as hemodialysis machines, dialyzers and related disposable products. Chronic kidney failure is a condition that affects about 2 million individuals worldwide. For more information about the company’s more than 1,800 U.S. dialysis facilities, visit www.ultracare-dialysis.com (in English and Spanish). For more information about Fresenius Medical Care, visit www.fmc-ag.com or www.fmcna.com

Legal Disclaimer:

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs